JP6186010B2 - Ｈｉｖ成熟阻害活性を有するｃ−１９修飾トリテルペノイド類 - Google Patents

Ｈｉｖ成熟阻害活性を有するｃ−１９修飾トリテルペノイド類 Download PDF

Info

Publication number
JP6186010B2
JP6186010B2 JP2015556998A JP2015556998A JP6186010B2 JP 6186010 B2 JP6186010 B2 JP 6186010B2 JP 2015556998 A JP2015556998 A JP 2015556998A JP 2015556998 A JP2015556998 A JP 2015556998A JP 6186010 B2 JP6186010 B2 JP 6186010B2
Authority
JP
Japan
Prior art keywords
mmol
cyclopenta
pentamethyl
octadecahydro
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015556998A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016507558A5 (enExample
JP2016507558A (ja
Inventor
ジェイコブ・スウィドースキ
ブライアン・リー・ベナブルズ
チェン・リウ
ニ・シン
ニコラス・エイ・ミーンウェル
アリシア・レゲイロ−レン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2016507558A publication Critical patent/JP2016507558A/ja
Publication of JP2016507558A5 publication Critical patent/JP2016507558A5/ja
Application granted granted Critical
Publication of JP6186010B2 publication Critical patent/JP6186010B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2015556998A 2013-02-06 2014-02-04 Ｈｉｖ成熟阻害活性を有するｃ−１９修飾トリテルペノイド類 Expired - Fee Related JP6186010B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361761403P 2013-02-06 2013-02-06
US61/761,403 2013-02-06
PCT/US2014/014647 WO2014123889A1 (en) 2013-02-06 2014-02-04 C-19 modified triterpenoids with hiv maturation inhibitory activity

Publications (3)

Publication Number Publication Date
JP2016507558A JP2016507558A (ja) 2016-03-10
JP2016507558A5 JP2016507558A5 (enExample) 2016-12-15
JP6186010B2 true JP6186010B2 (ja) 2017-08-23

Family

ID=50150818

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015556998A Expired - Fee Related JP6186010B2 (ja) 2013-02-06 2014-02-04 Ｈｉｖ成熟阻害活性を有するｃ−１９修飾トリテルペノイド類

Country Status (15)

Country Link
US (1) US20140221361A1 (enExample)
EP (1) EP2953960A1 (enExample)
JP (1) JP6186010B2 (enExample)
KR (1) KR20150115881A (enExample)
CN (1) CN105121454A (enExample)
AR (1) AR094684A1 (enExample)
AU (1) AU2014215468B2 (enExample)
BR (1) BR112015018491A2 (enExample)
CA (1) CA2900124A1 (enExample)
EA (1) EA027371B1 (enExample)
IL (1) IL240289A0 (enExample)
MX (1) MX2015010003A (enExample)
SG (1) SG11201505639SA (enExample)
TW (1) TW201443073A (enExample)
WO (1) WO2014123889A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906889B2 (en) * 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
KR20180028534A (ko) 2015-07-28 2018-03-16 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Hiv 감염을 예방하거나 치료하기 위한 베투인 유도체
RU2018105352A (ru) 2015-07-28 2019-08-29 ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед Производные бетулина для предупреждения или лечения ВИЧ-инфекций
WO2017025901A1 (en) * 2015-08-11 2017-02-16 Hetero Research Foundation Novel c28-analogues with c3-modifications of triterpene derivatives as hiv inhibitors
CN108368071A (zh) 2015-09-24 2018-08-03 葛兰素史克知识产权第二有限公司 具有hiv成熟抑制活性的化合物
CN108699103A (zh) 2016-01-20 2018-10-23 葛兰素史克知识产权第二有限公司 具有hiv成熟抑制活性的羽扇烷类的胺衍生物
AR107512A1 (es) * 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
WO2017149518A1 (en) * 2016-03-04 2017-09-08 Hetero Labs Limited C-3 novel triterpene with c-17 amine derivatives as hiv inhibitors
US10493070B2 (en) 2016-06-30 2019-12-03 Viiv Healthcare Uk (No. 5) Limited Azadecalin derivatives as inhibitors of human immunodeficiency virus replication
EP3506902A4 (en) * 2016-08-31 2020-04-22 VIIV Healthcare Company COMBINATIONS AND USES AND TREATMENTS THEREOF
WO2018044853A1 (en) * 2016-08-31 2018-03-08 Viiv Healthcare Conpany Combinations and uses and treatments thereof
WO2019207460A1 (en) 2018-04-24 2019-10-31 VIIV Healthcare UK (No.5) Limited Compounds with hiv maturation inhibitory activity
NZ769842A (en) * 2018-06-29 2023-01-27 Dfh Therapeutics Triterpene amine derivatives
MX2021009584A (es) 2019-02-11 2021-09-23 Hetero Labs Ltd Nuevos derivados de triterpeno como inhibidores del virus de la inmunodeficiencia humana (vih).

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2694048B2 (ja) * 1991-05-09 1997-12-24 日立建機株式会社 建設機械の油圧駆動装置
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
FR2683531B1 (fr) * 1991-11-13 1993-12-31 Rhone Poulenc Rorer Sa Nouveaux derives du lupane, leur preparation et les compositions pharmaceutiques qui les contiennent.
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
JP2007529544A (ja) 2004-03-17 2007-10-25 パナコス ファーマシューティカルズ， インコーポレイテッド ３−ｏ−（３’，３’−ジメチルスクシニル）ベツリン酸の製薬的な塩
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
US20110144069A1 (en) 2006-10-16 2011-06-16 Myriad Genetics, Incorporated Compounds for treating viral infections
CA2714049A1 (en) 2008-02-14 2009-08-20 Virochem Pharma Inc. Novel 17.beta. lupane derivatives
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
ES2612452T3 (es) 2010-06-04 2017-05-17 VIIV Healthcare UK (No.5) Limited Derivados de ácido betulínico C-3 modificados como inhibidores de la maduración del VIH
EP2576586B1 (en) * 2010-06-04 2015-08-12 Bristol-Myers Squibb Company C-28 amides of modified c-3 betulinic acid derivatives as hiv maturation inhibitors
WO2012006190A1 (en) 2010-06-29 2012-01-12 Huawei Technologies Co., Ltd. Delegate gateways and proxy for target hosts in large layer 2 and address resolution with duplicated internet protocol addresses
ES2653847T3 (es) 2011-01-31 2018-02-09 Viiv Healthcare Uk (No. 4) Limited Triterpenoides C-17 y C-3 modificados con actividad inhibitoria contra maduración del VIH
CN103339141B (zh) 2011-01-31 2016-08-24 百时美施贵宝公司 作为hiv成熟抑制剂的c-3修饰的桦木酸衍生物的c-28胺
US8906889B2 (en) 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
WO2013160810A2 (en) * 2012-04-24 2013-10-31 Hetero Research Foundation Novel betulinic acid derivatives as hiv inhibitors
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity

Also Published As

Publication number Publication date
TW201443073A (zh) 2014-11-16
WO2014123889A1 (en) 2014-08-14
SG11201505639SA (en) 2015-08-28
CA2900124A1 (en) 2014-08-14
US20140221361A1 (en) 2014-08-07
CN105121454A (zh) 2015-12-02
AU2014215468A1 (en) 2015-09-24
KR20150115881A (ko) 2015-10-14
JP2016507558A (ja) 2016-03-10
AU2014215468B2 (en) 2017-05-18
MX2015010003A (es) 2015-10-30
BR112015018491A2 (pt) 2017-07-18
IL240289A0 (en) 2015-09-24
EA201591406A1 (ru) 2015-12-30
EP2953960A1 (en) 2015-12-16
EA027371B1 (ru) 2017-07-31
AR094684A1 (es) 2015-08-19

Similar Documents

Publication Publication Date Title
JP6186010B2 (ja) Ｈｉｖ成熟阻害活性を有するｃ−１９修飾トリテルペノイド類
CN103429607B (zh) 具有hiv成熟抑制活性的c-17和c-3经修饰的三萜系化合物
JP6155285B2 (ja) Ｈｉｖ成熟阻害活性のあるｃ−３シクロアルケニルトリテルペノイド
JP6186012B2 (ja) Ｃ−３アルキルおよびアルケニル修飾ベツリン酸誘導体
JP5755731B2 (ja) Ｈｉｖ成熟阻害剤としての修飾ｃ−３ベツリン酸誘導体のｃ−２８アミド
JP6212545B2 (ja) Ｈｉｖ成熟阻害活性を有するｃ−１７二環式アミンのトリテルペノイド
JP6000283B2 (ja) Ｈｉｖ成熟阻害剤としてのｃ−３修飾ベツリン酸誘導体のｃ−２８アミン
KR102411082B1 (ko) 할로알킬 치환기를 지니는 비­방향족 고리에 의해 위치 3에서 치환된，ｈｉｖ 성숙화 억제 활성을 갖는 트리테르페노이드
ES2957767T3 (es) Triterpenoides modificados en C-3 y C-17 como inhibidores del VIH-1
HK40041853A (en) Triterpenoids with hiv maturation inhibitory activity
JP2017533934A (ja) Ｃ１７アリール置換ベツリン酸類似体
HK1232548B (en) Triterpenoids with hiv maturation inhibitory activity, substituted in position 3 by a non-aromatic ring carrying a haloalkyl substituent

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161024

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170606

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20170608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170616

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170725

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170728

R150 Certificate of patent or registration of utility model

Ref document number: 6186010

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees